On the Record · Bristol Myers Squibb
Bristol Myers Squibb acquisitions, on the record
The businesses Bristol Myers Squibb bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
MiratiWord for word“(i) the acquisition of Mirati, which was completed in January 2024; (ii) the planned acquisitions of Karuna and RayzeBio, which were announced in December 2023; and (iii) a global strategic collaboration agreement with SystImmune, which was announced in December 2023.” 10-K for 2023 | acquisition | completed in January 2024 | — |
KarunaWord for word“(ii) the planned acquisitions of Karuna and RayzeBio, which were announced in December 2023; and (iii) a global strategic collaboration agreement with SystImmune, which was announced in December 2023.” 10-K for 2023 | agreed acquisition | announced in December 2023 | — |
RayzeBioWord for word“(ii) the planned acquisitions of Karuna and RayzeBio, which were announced in December 2023; and (iii) a global strategic collaboration agreement with SystImmune, which was announced in December 2023.” 10-K for 2023 | agreed acquisition | announced in December 2023 | — |
Turning PointWord for word“partially offset by the acquisition of Turning Point ($3.2 billion net of cash acquired) in 2022.” 10-K for 2023 | acquisition | 2022 | $3.2 billion net of cash acquired |
Mavacamten rights buy-outWord for word“Mavacamten rights buy-out (Note 4) $ 445 $ — Orum upfront payment (Note 4) 100 — Mavacamten royalty extinguishment (Note 4) — 295 Dragonfly milestone and opt-in license fee — 200 Evotec designation and opt-in license fees 90 — BridgeBio upfront collaboration fee — 90 Prothena opt-in license fee 55 Zenas upfront license fee 50 — Immatics upfront license and opt-in fee (Note 4) 15 150 Other 158 80 Acquired IPRD $ 913 $ 815 Refer to “Item 8. Financial Statements and Supplementary Data—Note 3. Alliances” and “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for additional information.” 10-K for 2023 | acquisition | — | — |
diabetes businessWord for word“Royalties have continued to represent a significant percentage of our pretax income, including royalties related to the divestiture of our diabetes business (including the transfer of certain future royalty rights pertaining to Amylin, Onglyza* and Farxiga* product sales), out-licensed intellectual property and the Merck patent infringement settlement.” 10-K for 2023 | divestiture | — | — |
SystImmuneWord for word“We also entered into a strategic collaboration with SystImmune, to co-develop and co-commercialize izalontamab brengitecan (iza-bren or BL-B01D1), a bispecific topoisomerase inhibitor-based anti-body drug conjugate.” 10-K for 2024 | agreed acquisition | — | — |
Orbital TherapeuticsWord for word“In 2025, the Company (i) acquired Orbital Therapeutics, which provided the Company with full rights to OTX-201, a preclinical in vivo CAR T-cell therapy currently in IND-enabling studies for autoimmune disease, (ii) entered into a strategic collaboration with BioNTech to co-develop and co-commercialize BioNTech's investigational bispecific antibody pumitamig (BNT327/BMS986545) across multiple solid tumor types, (iii) acquired a global exclusive license from Philochem for OncoACP3, a radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer, and (iv) expanded our development and manufacturing capabilities by opening a new radiopharmaceutical facility in Indianapolis, Indiana, which will support RPTs acquired in connection with the RayzeBio acquisition.” 10-K for 2025 | acquisition | 2025 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-12-31 | $359 million | — |
| 2017-12-31 | $726 million | — |
| 2018-12-31 | $2.37 billion | — |
| 2019-12-31 | $24.78 billion | — |
| 2020-12-31 | $13.08 billion | — |
| 2021-12-31 | $1.61 billion | — |
| 2022-12-31 | $4.29 billion | — |
| 2023-12-31 | $1.17 billion | $0 |
| 2024-12-31 | $21.82 billion | $580 million |
| 2025-12-31 | $3.94 billion | $0 |
Deal filings since 2016
- 2022-03-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-02-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-11-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-11-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-02-05 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2019-11-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-22 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2019-11-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-20 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2019-05-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-01-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-01-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-01-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Bristol Myers Squibb’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-11. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.